NDTV-Dettol Banega Swasth Swachh India NDTV-Dettol Banega Swasth Swachh India
  • Home/
  • News/
  • Centre Fast Tracks Emergency Approvals For Foreign-Produced COVID-19 Vaccines


Centre Fast Tracks Emergency Approvals For Foreign-Produced COVID-19 Vaccines

A meeting of National Expert Group on Vaccine Administration for COVID-19 (NEGVAC) recommended increasing the basket of vaccines by including those which have been approved in other countries

Centre Fast Tracks Emergency Approvals For Foreign-Produced COVID-19 Vaccines
  • Russian-made vaccine Sputnik V has been cleared for emergency use by DGCI
  • Five more vaccines are expected to get approval this year: Centre
  • Vaccination is one of the critical pillars of COVID-19 control: Centre

New Delhi: The Central government has fast-tracked emergency approvals for foreign-produced COVID-19 vaccines that have been granted Emergency Use Authorization (EUA) in other countries to expand the basket of vaccines for domestic use and hasten the pace and coverage of vaccination, the Union Health Ministry said on Tuesday (April 13). The ministry said that India constituted a task force headed by Principal Scientific Advisor to encourage R&D for vaccine manufacture and constituted in August 2020 an Expert Group headed by Member, NITI to assist in the roll-out of the COVID-19 vaccination programme.

Also Read: Russia’s COVID-19 Vaccine Sputnik V Gets Approval Of Expert Committee In India

It further said that India became the first country to have two “Made in India” Covid vaccines for domestic vaccination drive because of these strategies. The matter of augmenting the basket of vaccines available for fighting the pandemic as well as accelerating the pace and coverage of domestic vaccination programme was discussed in the 23rd meeting of the National Expert Group on Vaccine Administration for COVID-19 (NEGVAC) held on April 11, 2021, chaired by Dr V K Paul, Member (Health), Niti Aayog.

The NEGVAC, after comprehensive deliberation, recommended that vaccines for COVID-19, which have been developed and are being manufactured in foreign countries and which have been granted emergency approval for restricted use by USFDA, EMA, UK MHRA, PMDA Japan or which are listed in WHO (Emergency Use Listing) may be granted emergency use approval in India, mandating the requirement of post-approval parallel bridging clinical trial in place of conduct of local clinical trial as per the provisions prescribed under Second Schedule of the New Drugs and Clinical Trials Rules 2019, it said.

The first 100 beneficiaries of such foreign vaccines will be assessed for seven days for safety outcomes before it is rolled out for further immunization programme within the country. The Union government, after due consideration, has accepted the recommendation of NEGVAC and this decision will facilitate quicker access to such foreign vaccines by India.

Also Read: India Fastest Nation To Administer Over 100 Million Doses Of COVID-19 Vaccine In 85 Days: Health Ministry

This will also encourage imports including import of bulk drug material, optimal utilisation of domestic fill and finish capacity etc., which will, in turn, provide a fillip to vaccine manufacturing capacity and total vaccine availability for domestic. The Ministry further added that vaccination is one of the critical pillars of COVID control and management strategy adopted by the Centre.

Presently two vaccines i.e. Covaxin by Bharat Biotech International Limited (BBIL) and Covishield by Serum Institute of India (SII), have received Emergency Use Authorization (EUA) from the National Regulator (Drugs Controller General of India), it said.

Also Read: India To Have Five More COVID Vaccines By October, Sputnik V Expected To Get Emergency Use Nod In 10 Days

(Except for the headline, this story has not been edited by NDTV staff and is published from a syndicated feed.)

NDTV – Dettol Banega Swasth India campaign is an extension of the five-year-old Banega Swachh India initiative helmed by Campaign Ambassador Amitabh Bachchan. It aims to spread awareness about critical health issues facing the country. In wake of the current COVID-19 pandemic, the need for WASH (WaterSanitation and Hygiene) is reaffirmed as handwashing is one of the ways to prevent Coronavirus infection and other diseases. The campaign highlights the importance of nutrition and healthcare for women and children to prevent maternal and child mortality, fight malnutrition, stunting, wasting, anaemia and disease prevention through vaccines. Importance of programmes like Public Distribution System (PDS), Mid-day Meal Scheme, POSHAN Abhiyan and the role of Aganwadis and ASHA workers are also covered. Only a Swachh or clean India where toilets are used and open defecation free (ODF) status achieved as part of the Swachh Bharat Abhiyan launched by Prime Minister Narendra Modi in 2014, can eradicate diseases like diahorrea and become a Swasth or healthy India. The campaign will continue to cover issues like air pollutionwaste managementplastic banmanual scavenging and sanitation workers and menstrual hygiene


Highlights: Banega Swasth India Launches Season 10

Reckitt’s Commitment To A Better Future

India’s Unsung Heroes

Women’s Health

हिंदी में पढ़ें

This website follows the DNPA Code of Ethics

© Copyright NDTV Convergence Limited 2024. All rights reserved.